<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01086111</url>
  </required_header>
  <id_info>
    <org_study_id>S51169</org_study_id>
    <nct_id>NCT01086111</nct_id>
  </id_info>
  <brief_title>The Effect of a Gastric Bypass on Type 2 Diabetes in the Morbidly Obese Patient</brief_title>
  <official_title>Mechanisms of Type 2 Diabetes Improvement, Besides Weightloss After Gastric Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gasthuisberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Gasthuisberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Proof of concept, of RYGBP and its capabilities to cure type 2 diabetes (DM 2) and sleep&#xD;
      apnea has already been recognized in the reports on weight loss surgery.&#xD;
&#xD;
      The investigators project aims to prove that RYGBP also recovers the beta cell function (BCF)&#xD;
      Clamp tests, the gold standard for testing IS and BCF, will be performed preoperative and&#xD;
      early postoperatively.&#xD;
&#xD;
      Aims &amp; methodology:&#xD;
&#xD;
      Analysis of the short-term effect of gastric bypass and sleeve gastrectomy on insulin&#xD;
      sensitivity and beta cell function.&#xD;
&#xD;
      Preoperative baseline insulin sensitivity and beta cell function will be assessed with&#xD;
      euglycemic and hyperglycemic clamp tests. These results will be compared with the results of&#xD;
      the same tests carried out 3 weeks postoperative.&#xD;
&#xD;
      To determine if the duodenal exclusion is causing this effect. The results of the clamp tests&#xD;
      3 weeks postoperative will be compared&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>insulin sensitivity and beta cell function</measure>
    <time_frame>3 weeks</time_frame>
    <description>insulin sensitivity and beta cell function changes 3 weeks after RYGB, sleeve gastrectomy and protein sparing diet using euglycaemic and hyperglycemic clamp techniques.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in plasma levels of gut hormones and inflammation markers</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Morbid Obesity</condition>
  <arm_group>
    <arm_group_label>PMSF</arm_group_label>
    <description>type 2 diabetes patient receiving a protein sparing diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sleeve gastrectomy</arm_group_label>
    <description>type 2 diabetes patient receiving a gastric bypass</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RYGBP</arm_group_label>
    <description>type 2 diabetes patient receiving a gastric bypass</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        type 2 diabetes patients with a BMI &gt; 35kg/m²&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female or male subjects aged 18 to 65&#xD;
&#xD;
          -  BMI &gt; 35 kg/m2&#xD;
&#xD;
          -  Subject is capable and willing to give informed consent.&#xD;
&#xD;
          -  In the surgical groups indication for surgery is approved by the local&#xD;
             multidisciplinary obesity workgroup following the NIH guidelines of 199112.&#xD;
&#xD;
          -  Patient suffers from type 2 diabetes necessitating insulin therapy.&#xD;
&#xD;
          -  Subject is a non-smoker for at least 6 months prior to study start.&#xD;
&#xD;
          -  Female patients of child bearing potential must use oral, injected or implanted&#xD;
             hormonal methods of contraception from at least the commencement of their last normal&#xD;
             period prior to the screening visit. Patients using hormonal contraception should use&#xD;
             a barrier method in addition from screening visit until their next normal period&#xD;
             following the end of the study.&#xD;
&#xD;
          -  Female patients of non-child bearing potential defined as:&#xD;
&#xD;
               -  Post-menopausal females, being amenorrhoeic for at least 1 year&#xD;
&#xD;
               -  Pre-menopausal females with a documented hysterectomy or bilateral oophorectomy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female patient is pregnant or breastfeeding.&#xD;
&#xD;
          -  BMI &lt; 35 kg/m2&#xD;
&#xD;
          -  Patient suffers from an endocrine disease, besides diabetes and thyroid disease, such&#xD;
             as Cushing's disease, Addison's disease, hypothalamic tumor…)&#xD;
&#xD;
          -  Patient suffers from type 1 diabetes, MODY or LADA&#xD;
&#xD;
          -  Patient has undergone previous surgical procedure for weight loss&#xD;
&#xD;
          -  Patient is considered ASA 4 or more according to the ASA physical status&#xD;
             classification system of the American Society of Anesthesiologists.&#xD;
&#xD;
          -  Patient suffers from liver cirrhosis&#xD;
&#xD;
          -  Patient uses steroids&#xD;
&#xD;
          -  Patient uses cyclosporin&#xD;
&#xD;
          -  Recent (&lt;30 days) or simultaneous participation in another clinical trial.&#xD;
&#xD;
          -  Any situation that can compromise the study, including serious illness or a&#xD;
             predictable lack of cooperation from the subject.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospitals Leuven, gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>March 10, 2010</study_first_submitted>
  <study_first_submitted_qc>March 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2010</study_first_posted>
  <last_update_submitted>December 3, 2015</last_update_submitted>
  <last_update_submitted_qc>December 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gasthuisberg</investigator_affiliation>
    <investigator_full_name>Matthias Lannoo</investigator_full_name>
    <investigator_title>medical doctor</investigator_title>
  </responsible_party>
  <keyword>type 2 diabetes</keyword>
  <keyword>gastric bypass</keyword>
  <keyword>sleeve gastrectomy</keyword>
  <keyword>clamp study</keyword>
  <keyword>weight loss surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

